Non-adherence to therapy in chronic disease leads to poor outcomes and to a high cost. It is estimated that rate of adherence to chronic medications is only in the 50% range - responsible for half of all treatment failures and up to 25% of US hospitalizations each year. Dir to this reality, Simmbion, LLC, located in Baltimore, Md., is working to develop a long-term cellular factory approach for the delivery biologics similar to insulin and GLP-1 to hopefully deliver safer treatments and reduce the cost and time of care. This synthetic cell technology possesses features such as being disease-agnostic, tunable and universally immune-compatible and requires only minimal cold-chain logistics.
